Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose

详细信息	查看全文 | 推荐本文 |

• 作者：Jennifer Humberd Smith^a ; Mark Papania^c ; Darin Knaus^d ; Paula Brooks^a ; Debra L. Haas^a ; Raydel Mair^b ; James Barry^d ; S. Mark Tompkins^a ; Ralph A. Tripp^a ; ^{ratripp@uga.edu}
• 关键词：Influenza ; Vaccine ; Dose-sparing ; Ferret ; Aerosol
• 刊名：Vaccine
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：19 April, 2012
• 卷：30
• 期：19
• 页码：3026-3033
• 文件大小：333 K

摘要

Live-attenuated influenza vaccine (LAIV) is delivered to vaccine recipients using a nasal spray syringe. LAIV delivered by this method is immunogenic at current doses; however, improvements in nasal delivery might allow for significant dose reduction. We investigated LAIV vaccination in ferrets using a high efficiency nebulizer designed for nasal delivery. LAIV nasal aerosol elicited high levels of serum neutralizing antibodies and protected ferrets from homologous virus challenge at conventional (10⁷ TCID₅₀) and significantly reduced (10³ TCID₅₀) doses. Aerosol LAIV also provided a significant level of subtype-specific cross-protection. These results demonstrate the dose-sparing potential of nebulizer-based nasal aerosol LAIV delivery.